IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A <u>mammalian</u> cell of <u>mammals</u> which is loaded with <u>a</u> bacteria for the prophylaxis or therapy of a disorder,

where wherein the cell is autologous, allogeneic or xenogeneic and is selected from the group consisting of "macrophages, dentritic cells, granulocytes, lymphocytes, tumor cells and tissue cells."

Claim 2 (Currently Amended): The <u>mammalian</u> cell as claimed in claim 1, which is inactivated by irradiation or other methods.

Claim 3 (Currently Amended): The <u>mammalian</u> cell as claimed in claim 1-or-2, where <u>wherein</u> the bacteria are alive, nonvirulent, virulence-attenuated, or dead.

Claim 4 (Currently Amended): The mammalian cell as claimed in any of claims 1 to 3, where claim 1, wherein the bacteria are selected from the group consisting of "Mycobacterium tuberculosis, M. bovis, M. bovis strain BCG, BCG substrains, M. avium, M. intracellailare, M. africanum, M. kansasil, M. marinum, M. ulcerans, M. avium subspecies paratuberculosis, Norcardia asteroides, other Nocardia species, Legionella pneumophila, other Legionella species, Salmonella typhi, S. typhimurium, other Salmonella species, Shigella species, Yersinia pestis, Pasteurella haemolytica, Pasteurella multocida, other Pasteurella species, Actinobacillus pleuropneumoniae, Listeria monocytogenes, L. ivanovii,

Brucella abortus, other Brucella species, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydia psittaci, and Coxiella burnetii².

Claim 5 (Currently Amended): The <u>mammalian</u> cell as claimed in any of claims 1 to 4, where <u>claim 1</u>, wherein the bacteria harbor recombinant DNA, the <u>DNA coding for that</u> encodes at least one active substance.

Claim 6 (Currently Amended): The <u>mammalian</u> cell as claimed in any of claims 1 to 5, where claim 5, wherein at least one active substance is produced by the bacteria themselves with the aid of suitable promoters, or <u>the</u> expression thereof is under the control of a eukaryotic promoter.

Claim 7 (Currently Amended): The <u>mammalian</u> cell as claimed in any of claims 1 to 6, where claim 1, wherein the bacteria produces an active substance that localizes intracellularintracellularly, membrane that is associated with a membrane of the bacteria, or that is secreted.secretory production takes place.

Claim 8 (Currently Amended): The <u>mammalian</u> cell as claimed in <u>any of claims 1 to</u>
7, where <u>claim 1</u>, wherein the active substance is selected from the group consisting of
"antigens of infectious agents such as viruses, bacteria, mycoplasma, parasites, antigens
specific for tumors, in particular proteins encoded by oncogenes, antibodies, epitope-binding
fragments of antibodies, and fusion proteins comprising at least one epitope binding fragment
of an antibody directed for example against an antigen on a tumor cell, on a lymphocyte such
as, for example, a T lymphocyte or on an endothelial cell such as, for example, a tumor

endothelial cell, enzymes, in particular enzymes for activating inactive precursors of a medicament such as, for example, a β -glucuronidase, a phosphatase, a hydrolase, a lipase, imunospuppressant cytokines-such as, for example IL-10, immunostimulating cytokines-such as, for example, IL-1, IL-2, Il-3, or IL-6, chemokines, interferons, growth factors-such as for example, G-CSF, GM-CSF, M-CSF, FGF; VEGF or EGF, or and inhibitory proteins or growth factors.

Claim 9 (Currently Amended): The use of a cell as claimed in any of claims 1 to 8 A method for the prophylaxis or therapy of a disorder, comprising:

administrating an effective amount of a mammalian cell of claim 1 to a subject, where wherein the active substance and/or vaccine antigen produced by the bacteria blocks negative regulatory elements in the a tumor tissue.

Claim 10 (Currently Amended): The use of a cell as claimed in any of claims 1 to 8 for the prophylaxis or therapy of a disorder, where The method of claim 9, wherein the bacteria serve as a proinflammatory stimulant in a tumor tissue.

Claim 11 (Currently Amended): The use of a cell as claimed in any of claims 1 to 8 for the prophylaxis or therapy of a disorder, where The method of claim 9, wherein dendritic cells or macrophages are employed simultaneously as a carrier for a the vaccine antigen.

Claim 12 (Currently Amended): The use of a cell as claimed in any of claims 1 to 8 for the prophylaxis or therapy of a disorder, where The method of claim 9, wherein the active

substance and/or the vaccine antigen is loaded ex vivo onto the dentritic cells or onto the macrophages.

Claim 13 (Currently Amended): The use as claimed in claim 12), where The method of claim 12, wherein the vaccine antigen consists of comprises defined peptides.

Claim 14 (Currently Amended): The use as claimed in claim 10), where The method of claim 9, wherein the mammalian cell is fused to another cell which expresses a tissue antigen or a tumor antigen.

Claim 15 (Currently Amended): The use as claimed in claim 14, where The method of claim 14, wherein the fused cells are autologous tumor cells.

Claim 16 (Cancelled)

Claim 17 (Currently Amended): The use of a cell, in particular a claimed in any of elaims 1 to 8, The method of claim 9, wherein which is loaded with a the bacteria is a microorganism comprising that comprises a foreign DNA, in particular bacterial microorganism, for producing a pharmaceutical composition.

Claim 18 (Currently Amended): The use as claimed in claim 17, where The method of claim 17, wherein the foreign DNA codes for a defined active substance, and where wherein the a pharmaceutical composition is intended for the prophylaxis or treatment of a disorder which can be prevented and/or treated with the active substance.

Claim 19 (New): The mammalian cell of claim 8, wherein the infectious agent is a virus, a bacteria, a mycoplasma, or a parasite.

Claim 20 (New): The mammalian cell of claim 8, wherein the enzyme is an enzyme for activating inactive precursors of a medicament.

Claim 21 (New): The mammalian cell of claim 20, wherein the enzyme for activating inactive precursors of a medicament is a β -glucuronidase, a phosphatase, a hydrolase, or a lipase.

Claim 22 (New): The mammalian cell of claim 8, wherein the imunospuppressant cytokine is IL-10.

Claim 23 (New): The mammalian cell of claim 8, wherein the immunostimulating cytokine is IL-1, IL-2, IL-3, IL-6, a chemokine, or an interferon.

Claim 24 (New): The mammalian cell of claim 8, wherein the growth factor is G-CSF, GM-CSF, M-CSF, FGF, VEGF, or EGF.

Claim 25 (New): The mammalian cell of claim 8, wherein the inhibitory protein is specific for a cytokine, a chemokine, an interferon, or a growth factor.

Preliminary Amendment Docket No. 281782US0PCT

Claim 26 (New): The mammalian cell of claim 8, wherein the fusion protein comprises at least one epitope-binding fragment of an antibody directed against an antigen on a tumor cell, a lymphocyte, or an endothelial cell.

Claim 27 (New): The mammalian cell of claim 26, wherein the lymphocyte is a T lymphocyte.

Claim 28 (New): The mammalian cell of claim 26, wherein the endothelial cell is a tumor endothelial cell.

7